Chris Lau

InvestorPlace Contributor

Expertise: Technology, Biotech

Expertise:

Technology
Biotech

Education:

Bachelor of Science
Project Management Professional

Awards and Accomplishments:

Top 100 Tipranks 2015-2021

About Chris:

Chris has over two decades of investing experience. He is an Honors B.Sc graduate (with distinction) in Science and Economics. He holds a Project Management Professional designation

Chris focuses on the technology, cyclical, and healthcare sector. He runs a newsletter with speculative Triple-baggers.

His investment strategy is based on finding undervalued stocks trading at a steep discount to their intrinsic value.

Follow Chris on DIY Value Investing.

Recent Articles

5 Hot Marijuana Stocks as Beer Companies Shop for an Acquisition

By Chris Lau, InvestorPlace Contributor Jun 26, 2018

After taking a pause in its uptrend, marijuana stocks could get a lift again as Molson Coors shops for companies in this sector. Though the sector has yet to prove it is profitable, a buyout will lift nearly all marijuana stocks.

Why Tandem Stock Could Continue Its Rally

By Chris Lau, InvestorPlace Contributor Jun 25, 2018

Tandem stock rocketed to a new high after the company won an FDA approval and two analyst upgrades. At a one billion dollar market cap, the stock still has upside.

Why Gevo, Inc. Stock Soared 262% Yesterday

By Chris Lau, InvestorPlace Contributor Jun 19, 2018

Gevo jumped a mouth-watering 261.82% in a single day. However, looking more closely in the company shows that investors will need to exercise caution.

Can Sprout Pharma’s Latest Revival Really Boost VRX Stock?

By Chris Lau, InvestorPlace Contributor Jun 15, 2018

Sprout Pharma is about to revive the libido pill, Addyi. With the same leadership but autonomy from Valeant Pharma, Sprout could turn the drug into a success story.

Teva Pharmaceutical Industries Limited Stock Still Is a Deep Value Play